Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation

S. D. Chernausek, B. A. Dickson, E. P. Smith, S. B. Hoath

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Epidermal growth factor (EGF) attenuates growth when administered to rats <2 wk of age but lacks growth-retarding properties when given to older animals. Because the insulin-like growth factors (IGF) are postulated to be important regulators of somatic growth during the perinatal period, we examined the effect of exogenous EGF on serum and tissue concentrations of IGF-I and hepatic expression of mRNA for IGF-I and IGF-II. A single injection of EGF (500 ng/g body wt) produced a significant (P < 0.01) decline in serum IGF-I concentration within 4 h in newborn rat pups [controls, 46.2 ± 9.1 (SD) ng/ml; EGF treated, 29.4 ± 4.0 ng/ml] but was ineffective in 2-wk-old animals (control IGF-I, 72.8 ± 15.1 vs. 64.0 ± 13.7 ng/ml). When the EGF was given on days 0-3 of life, circulating IGF-I concentrations were suppressed further (control, 61.4 ± 8.6; EGF treated, 32.5 ± 8.6 ng/ml). Despite the change in circulating IGF-I levels in the newborn rats, the amount of IGF-I extractable from liver and kidney of growth-retarded animals was not significantly different from control. Likewise, IGF-I and IGF-II mRNA expression in liver, as assessed by blot hybridization, was unchanged by the EGF treatment. The rapid decline in IGF-I concentration after EGF administration, coupled with the restriction of this phenomenon the first 2 wk of extrauterine life, implies that changes in IGF-I are involved in the pathogenesis of EGF-induced growth retardation.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume260
Issue number3 23-3
StatePublished - 1991

Fingerprint

Insulin-Like Growth Factor I
Epidermal Growth Factor
Growth
Animals
Insulin-Like Growth Factor II
Liver
Rats
Rat control
Messenger RNA
Somatomedins
Serum
Tissue
Kidney
Injections

Keywords

  • Perinatal growth
  • Rat
  • Somatomedins

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology

Cite this

Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation. / Chernausek, S. D.; Dickson, B. A.; Smith, E. P.; Hoath, S. B.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 260, No. 3 23-3, 1991.

Research output: Contribution to journalArticle

@article{9e3c2162b79343639c36630634ce28bb,
title = "Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation",
abstract = "Epidermal growth factor (EGF) attenuates growth when administered to rats <2 wk of age but lacks growth-retarding properties when given to older animals. Because the insulin-like growth factors (IGF) are postulated to be important regulators of somatic growth during the perinatal period, we examined the effect of exogenous EGF on serum and tissue concentrations of IGF-I and hepatic expression of mRNA for IGF-I and IGF-II. A single injection of EGF (500 ng/g body wt) produced a significant (P < 0.01) decline in serum IGF-I concentration within 4 h in newborn rat pups [controls, 46.2 ± 9.1 (SD) ng/ml; EGF treated, 29.4 ± 4.0 ng/ml] but was ineffective in 2-wk-old animals (control IGF-I, 72.8 ± 15.1 vs. 64.0 ± 13.7 ng/ml). When the EGF was given on days 0-3 of life, circulating IGF-I concentrations were suppressed further (control, 61.4 ± 8.6; EGF treated, 32.5 ± 8.6 ng/ml). Despite the change in circulating IGF-I levels in the newborn rats, the amount of IGF-I extractable from liver and kidney of growth-retarded animals was not significantly different from control. Likewise, IGF-I and IGF-II mRNA expression in liver, as assessed by blot hybridization, was unchanged by the EGF treatment. The rapid decline in IGF-I concentration after EGF administration, coupled with the restriction of this phenomenon the first 2 wk of extrauterine life, implies that changes in IGF-I are involved in the pathogenesis of EGF-induced growth retardation.",
keywords = "Perinatal growth, Rat, Somatomedins",
author = "Chernausek, {S. D.} and Dickson, {B. A.} and Smith, {E. P.} and Hoath, {S. B.}",
year = "1991",
language = "English (US)",
volume = "260",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3 23-3",

}

TY - JOUR

T1 - Suppression of insulin-like growth factor I during epidermal growth factor-induced growth retardation

AU - Chernausek, S. D.

AU - Dickson, B. A.

AU - Smith, E. P.

AU - Hoath, S. B.

PY - 1991

Y1 - 1991

N2 - Epidermal growth factor (EGF) attenuates growth when administered to rats <2 wk of age but lacks growth-retarding properties when given to older animals. Because the insulin-like growth factors (IGF) are postulated to be important regulators of somatic growth during the perinatal period, we examined the effect of exogenous EGF on serum and tissue concentrations of IGF-I and hepatic expression of mRNA for IGF-I and IGF-II. A single injection of EGF (500 ng/g body wt) produced a significant (P < 0.01) decline in serum IGF-I concentration within 4 h in newborn rat pups [controls, 46.2 ± 9.1 (SD) ng/ml; EGF treated, 29.4 ± 4.0 ng/ml] but was ineffective in 2-wk-old animals (control IGF-I, 72.8 ± 15.1 vs. 64.0 ± 13.7 ng/ml). When the EGF was given on days 0-3 of life, circulating IGF-I concentrations were suppressed further (control, 61.4 ± 8.6; EGF treated, 32.5 ± 8.6 ng/ml). Despite the change in circulating IGF-I levels in the newborn rats, the amount of IGF-I extractable from liver and kidney of growth-retarded animals was not significantly different from control. Likewise, IGF-I and IGF-II mRNA expression in liver, as assessed by blot hybridization, was unchanged by the EGF treatment. The rapid decline in IGF-I concentration after EGF administration, coupled with the restriction of this phenomenon the first 2 wk of extrauterine life, implies that changes in IGF-I are involved in the pathogenesis of EGF-induced growth retardation.

AB - Epidermal growth factor (EGF) attenuates growth when administered to rats <2 wk of age but lacks growth-retarding properties when given to older animals. Because the insulin-like growth factors (IGF) are postulated to be important regulators of somatic growth during the perinatal period, we examined the effect of exogenous EGF on serum and tissue concentrations of IGF-I and hepatic expression of mRNA for IGF-I and IGF-II. A single injection of EGF (500 ng/g body wt) produced a significant (P < 0.01) decline in serum IGF-I concentration within 4 h in newborn rat pups [controls, 46.2 ± 9.1 (SD) ng/ml; EGF treated, 29.4 ± 4.0 ng/ml] but was ineffective in 2-wk-old animals (control IGF-I, 72.8 ± 15.1 vs. 64.0 ± 13.7 ng/ml). When the EGF was given on days 0-3 of life, circulating IGF-I concentrations were suppressed further (control, 61.4 ± 8.6; EGF treated, 32.5 ± 8.6 ng/ml). Despite the change in circulating IGF-I levels in the newborn rats, the amount of IGF-I extractable from liver and kidney of growth-retarded animals was not significantly different from control. Likewise, IGF-I and IGF-II mRNA expression in liver, as assessed by blot hybridization, was unchanged by the EGF treatment. The rapid decline in IGF-I concentration after EGF administration, coupled with the restriction of this phenomenon the first 2 wk of extrauterine life, implies that changes in IGF-I are involved in the pathogenesis of EGF-induced growth retardation.

KW - Perinatal growth

KW - Rat

KW - Somatomedins

UR - http://www.scopus.com/inward/record.url?scp=0025731249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025731249&partnerID=8YFLogxK

M3 - Article

VL - 260

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3 23-3

ER -